Treatment and Outcomes of Oropharyngeal Cancer in People with Human Immunodeficiency Virus.
Publication/Presentation Date
10-1-2019
Abstract
HIV-positive people are at increased risk for malignancies associated with human papillomavirus (HPV) infection, including oropharyngeal squamous cell carcinoma (OPSCC). The purpose of this study was to determine whether cancer treatment disparities exist between HIV-positive and HIV-negative people with OPSCC. We conducted a retrospective cohort study comparing OPSCC treatment adequacy and treatment outcomes in HIV-positive and HIV-negative people in the post-antiretroviral therapy era. Treatment adequacy was determined by measuring two primary endpoints associated with OPSCC survival: time to therapy and total radiation dose. Treatment outcomes were assessed by measuring disease-free and overall survival. We identified a total of 37 HIV-positive and 149 HIV-negative people with OPSCC. HIV-positive people experienced a median delay of 10 days from time of OPSCC diagnosis to start of therapy compared with HIV-negative people [hazard ratio (HR) 0.61, 95% confidence interval (CI) 0.38-0.98]. Total post-radiation dose in HIV-positive people was lower than that in HIV-negative people [58.5 Gray (Gy) versus 64.4 Gy,
Volume
35
Issue
10
First Page
934
Last Page
940
ISSN
1931-8405
Published In/Presented At
Brickman, C. E., Propert, K. J., Merlin, J. S., Liu, J. C., Eady, S., Mcghee-Jez, A., Ragin, C., Grover, S., Cohen, R. B., & Gross, R. (2019). Treatment and Outcomes of Oropharyngeal Cancer in People with Human Immunodeficiency Virus. AIDS research and human retroviruses, 35(10), 934–940. https://doi.org/10.1089/AID.2019.0009
Disciplines
Medicine and Health Sciences
PubMedID
31347379
Department(s)
Department of Surgery
Document Type
Article